EUVIMEDEUVIMED entdecken
Übersichtsarbeit

How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation

Qianyu Wang iD, Xiaofei Shen, Gang Chen, Junfeng Du

International Journal of Cancer · 15.08.2023 · 153 (4) · 709-722

DOI: 10.1002/ijc.34464 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Cancer, 2023-03. Verfasst von Qianyu Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Medical Department of General Surgery, The 1st Medical Center, Chinese PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Colorectal Neoplasms. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 150 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy, especially with immune checkpoint inhibitors (ICIs), has shown advantages in cancer treatment and is a new hope for patients who have failed multiline therapy. However, in colorectal cancer (CRC), the benefit is limited to a small subset of patients with microsatellite instability‐high (MSI‐H) or mismatch repair‐deficient (dMMR) metastatic CRC (mCRC). In addition, 45% to 60% of dMMR/MSI‐H mCRC patients showed primary or acquired resistance to ICIs. This means that these patients may have potential unknown pathways mediating immune escape. Almost all mismatch repair‐proficient (pMMR) or microsatellite‐stable (MSS) mCRC patients do not benefit from ICIs. In this review, we discuss the mechanisms of action of ICIs and their current status in CRC. We then discuss the mechanisms of primary and acquired resistance to ICIs in CRC. Finally, we discuss promising therapeutic strategies to overcome resistance to ICIs in the clinic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsColorectal NeoplasmsDNA Mismatch RepairMicrosatellite InstabilityNeoplastic Syndromes, HereditaryHumansBrain NeoplasmsImmunotherapy

Stichwörter der Autor:innen

colorectal cancerdrug resistanceimmune checkpoint inhibitorsmechanismtreatment

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Medical Department of General Surgery, The 1st Medical Center, Chinese PLA General Hospital, Beijing, China.
  • The Second School of Clinical Medicine, Shanxi Medical University, Taiyuan, China.
  • Department of General Surgery, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.
  • Department of General Surgery, The 7th Medical Center, Chinese PLA General Hospital, Beijing, China.
  • The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.

ORCID-Profile: Qianyu Wang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wang, Q., Shen, X., Chen, G., & Du, J. (2023). How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation. International Journal of Cancer, 153(4), 709-722. https://doi.org/10.1002/ijc.34464

Vancouver

Wang Q, Shen X, Chen G, Du J. How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation. International Journal of Cancer. 2023;153(4):709-722. doi:10.1002/ijc.34464

BibTeX
@article{Wang2023,
  author = {Wang, Qianyu and Shen, Xiaofei and Chen, Gang and Du, Junfeng},
  title = {How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation},
  journal = {International Journal of Cancer},
  year = {2023},
  volume = {153},
  number = {4},
  pages = {709--722},
  doi = {10.1002/ijc.34464}
}
Kostenlos starten →